Adult vaccination in Brazil: a cross-sectional survey on physicians' prescription habits

Authors: Fernando B Serra ¹; Diogo Ribeiro²; Paula M Batista¹; Thais N F Moreira¹
Affiliations: ¹MSD Brazil, São Paulo, Brazil; ²CTI Clinical Trial & Consulting Services, Lisboa, Portugal

Corresponding author:

Thais das Neves Fraga Moreira

MSD Brazil

Avenida Chucuri Zaidan, 296

Vila Cordeiro – São Paulo/SP – Brazil - ZIP CODE : 04583-110

Phone: +55 11 51897204

Email: thais.moreira@merck.com

Field Code Changed

Authors' emails and phone numbers:

Fernando B Serra – fernando.brandao.serra@merck.com; (55)11 5189 7584

Diogo Ribeiro – dribeiro@ctifacts.com; (351) 21 382 54 40

Paula M Batista – paula.de.mendonca.batista@merck.com; (55) 11 5189 7679

Thais N F Moreira – thais.moreira@merck.com; (55) 11 5189 7204

Title in Portuguese: Vacinação de adultos no Brasil: uma pesquisa transversal sobre os hábitos de prescrição dos médicos

Short Title: Adult vaccination in Brazil

ABSTRACT

OBJECTIVE

To characterize adult and older adult vaccination practices of physicians, from various medical specialties, in Brazil; identify barriers influencing prescription of vaccines to these populations, and evaluate the physicians' knowledge on routinely prescribed vaccines.

METHODS

Cross-sectional survey conducted in Brazil between June-August 2018. Eligible physicians included those from general practice/family medicine, geriatrics, cardiology, gynecology, endocrinology, infectious disease and pulmonology. The survey's questions addressed the physicians' prescription habits, sociodemographic and clinical practice characteristics, barriers to vaccines' prescription, and physicians' knowledge regarding routinely prescribed vaccines. The study focused on the vaccines recommended by the Brazilian Society of Immunization (SBIIm) for adults and older adults (years 2017-2018). Study sample was stratified according to the number of physicians per specialty and Brazilian region.

RESULTS

A total of 1068 surveys were completed. The vaccines prescribed by the highest proportions of physicians were Influenza (>90% of physicians for adults and older adults), Hepatitis B (adults: 87%; older adults: 59%) and Yellow Fever (adults: 77.7%; older adults: 58.5%). Underprescription was reported by less than 20% of prescribing physicians for all adult and older adult recommended vaccines. The most common barriers to vaccination were the high vaccine cost, lack of time during appointments

and lack of patient interest. Knowledge on target populations, dosage schedule and availability in the Unified Public Health System (SUS) was generally low.

CONCLUSIONS

The results showed a considerable variability of prescribing habits across recommended vaccines. Although most prescribing physicians seem to be aware of the importance of adult and older adult vaccination, knowledge deficits on vaccines' target populations, dosage schedule and availability in the SUS may hamper their ability to prescribe vaccines to all patients with an indication.

Keywords: Prescription habits, Vaccine knowledge, Adults, Older adults

INTRODUCTION

Vaccines are recommended throughout a person's lifetime to avert vaccine-preventable diseases (VPDs) and their complications¹. In Brazil, the National Immunization Program (NIP) supplies free-of-charge vaccines to all age groups as part of a defined immunization schedule². Currently, five vaccines are provided to adults (Influenza, Hepatitis B, Yellow Fever, Tetanus and diphtheria [Td], and Measle, mumps and rubella [MMR]), of which four are also provided to older adults (all except MMR)³. In addition, the Brazilian Society of Immunization (SBIIm) annually issues immunization schedules for adults (20-59 years)⁴, older adults (≥60 years)⁵, and special populations at increased risk of VPDs⁶.

Age-related disorders and comorbid conditions, such as diabetes, cardiovascular diseases, and cancer increase the risk and severity of VPDs⁷⁻⁹. Acute infectious diseases can also reduce functional capacity in older adults in the short and long term¹⁰. Thus, attaining an appropriate vaccination coverage represents an important public health strategy for healthy aging, capable of reducing mortality, morbidity and of improving quality of life among these patients^{7, 9, 11}.

Studies have reported that adult vaccination coverage rate (VCR) is still at a suboptimal level in various countries^{12, 13}, including Brazil^{14, 15}. This has been attributed to limited public awareness, misinformation, vaccine hesitancy, gaps in recommending vaccines during healthcare visits and vaccine costs^{1, 16}. In Brazil, the target for Influenza VCR (80%), which is delivered in mass campaigns supported by strong media communication, has been consistently met since 2011 in older adults¹⁷. However, a considerably lower coverage has been reported among patients with diabetes (47.2% in 2015)¹⁴. Furthermore, studies have also shown inadequate

87 pneumococcal VCR in adults and older adults (50.8%)¹⁵, especially in diabetic
 88 patients (26.1%)¹⁴.

89 Detailed understanding of factors responsible for low VCR among adult populations
 90 is required to establish effective immunization strategies. Studies on physicians'
 91 behavior toward adult vaccination are presently lacking, despite the fact that
 92 physicians' recommendations represent the leading factor to influence patients'
 93 adherence ^{18, 19}. Thus, this study aimed to characterize vaccination practices of
 94 physicians from various medical specialties in Brazil (general practice (GP)/family
 95 medicine (FM), geriatrics, cardiology, gynecology, endocrinology, infectious disease
 96 and pulmonology). We also intended to identify the barriers influencing vaccine
 97 prescriptions and physicians' knowledge regarding routinely prescribed vaccines.

METHODS

This was a national, cross-sectional study conducted between June and August 2018 in Brazil. Study data were collected through an online survey self-completed by eligible physicians. The survey's questions addressed the physicians' prescription habits, sociodemographic and clinical practice characteristics, barriers to the prescription of vaccines to adult and older adult patients, and physicians' knowledge regarding routinely prescribed vaccines. This study focused exclusively on the vaccines recommended by the SBIm for adults and older adults in the years 2017/2018^{4, 5} – Box 1.

Box 1 – Brazilian Society of Immunization's recommendations for adult and older adults at the time of the study (2017-2018).

This study was approved by the Ethics Committee of Universidade Federal de São Paulo.

Physicians' prescription habits

In terms of prescription habits, the survey collected the information depicted in Figure 1 for each adult and older adult recommended vaccine.

Figure 1 – Information collected on prescription habits for adult and older adult SBIm recommended vaccines.

Underprescription was defined as prescribing less than recommended by the SBIm and NIP. The survey did not provide the immunization recommendations from these entities and responding physicians were expected to use their own knowledge of these recommendations to identify and report underprescription.

Physicians' knowledge on routinely prescribed vaccines

The survey assessed the physicians' knowledge regarding the recommended vaccines' target populations, dosage schedule, and availability in SUS. We used the most up-to-date immunization schedules issued by the SBIm for adults⁴ and older adults⁵ (2017-2018) and special populations (2015-2016)²⁰ at the time of the study to define the correct answers. For availability in SUS, the correct answers for 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent human papillomavirus (HPV) vaccine considered more recent information published by the Ministry of Health instead^{21, 22}. All correct answers are detailed in Supplementary Table 1 (for target populations), Table 2 (for dosage schedule) and Table 3 (for availability in SUS).

For target populations, physicians should select the age groups (Adults [20-59 years] and/or Older adults [>60 years]) for which each vaccine is recommended, as well as the respective special populations. The physicians' knowledge on this topic was assessed by means of an overall score. This score, ranging from zero to one, was calculated based on the individual scores obtained by each physician in the question regarding target populations. The individual score corresponded to the ratio between the number of correct options selected by the physician and the total number of correct answers defined for each recommended vaccine. Each incorrect option

selected nullified a correct one. The only exception to this rule occurred when a SBIm recommendation did not encompass all patients within a given subpopulation (e.g., varicella vaccine is recommended for patients with HIV/AIDS, but not for those with CD4 <200 cells/mm³). In these cases, the option pertaining to the special population was considered correct, but did not nullify a correct one if not selected.

Physicians' knowledge on dosage schedules and availability in the SUS was assessed by determining the proportions of correct answers in the respective survey questions. The correct answers for availability in the SUS focused on whether the vaccines were available free of charge at the basic health units (BHUs).

Sample size

A sample of 1068 physicians was needed to determine the proportion of physicians prescribing each SBIm recommended vaccine, with a margin of error of 3% and a significance level of 0.05. In the absence of data on the proportion of prescribing physicians for SBIm recommended vaccines, we followed the most conservative approach by considering a proportion of 50%.

The sample was stratified according to the number of active physicians per Brazilian region and medical specialty (Supplementary Table 4). This was based on the number of active physicians in Brazil (overall and per region) according to the Federal Council of Medicine's website²³ and on the distribution of physicians across medical specialties of interest, as described by Scheffer M. et al²⁴ – see Supplementary Material for a detailed description of this process.

Recruitment of physicians

The recruitment of physicians was based on the Fine Panel, a large physicians' panel covering Brazil and other Latin America countries. The recruitment of physicians for this is based on various sources: public information and websites, contacts of affiliated physicians provided by hospitals and medical associations, contacts obtained during visits to hospitals and clinics, voluntary registrations and peer-to-peer recommendations from registered physicians. Physicians were eligible to complete the survey if they had a valid registration in the Fine Panel, either before or after being invited to participate in the study. Additionally, physicians had to meet all the following criteria: 1) worked at a public and/or private medical institution in Brazil; 2) belonged to one of the medical specialties of interest; 3) saw at least 30 patients per week. Conversely, physicians were not eligible if a sufficient number of physicians from the same medical specialty and Brazilian region had already completed the survey.

Statistical Analysis

Qualitative variables were summarized by absolute and relative frequencies. For the proportion of physicians prescribing each recommended vaccine, 95% confidence intervals were also computed. Quantitative variables were summarized by descriptive statistics, namely mean, median, standard deviation, minimum and maximum.

RESULTS

Study sample construction

A total of 76 104 physicians were invited to participate in the study to obtain 1068 completed surveys. Of these, 759 surveys were completed by physicians registered in the Fine Panel before being invited to participate (8 741 invitations), while the remaining 309 were completed by physicians who registered after receiving the invitation (67 364 invitations). The characteristics of the general population of physicians in Brazil, those invited to participate in the study, and those completing the survey are described in Supplementary Table 13.

Sociodemographic and clinical practice characterization

Almost half of the physicians (48.2%) were gynecologists – Table 1. On average, physicians had been practicing their medical specialty for 17.1 (± 10.0) years and prescribing vaccines to adults and/or older adults for 13.9 (± 8.3) years. Most physicians (89.9%) routinely recommended vaccines.

Table 1 – Participants' sociodemographic and clinical practice characteristics

Prescription habits

The proportions of physicians prescribing each recommended vaccine (to all or some of their patients with an indication) are summarized in Table 2.

Table 2 – Physicians prescribing and underprescribing vaccines recommended by the Brazilian Society of Immunization to adult and older adults

The vaccines prescribed by the highest proportions of physicians to adults and older adults were Influenza ($\geq 90\%$ of physicians in both groups), Hepatitis B (87% for adults and 59% for older adults) and Yellow Fever (77.7% for adults and 58.5% for older adults). Conversely, Meningococcal B (18.8%) and Meningococcal conjugated ACWY (20.2%) were prescribed by the lowest proportions of physicians for adults and older adults, respectively.

Prescription of vaccines to all patients with an indication

The proportion of prescribing physicians who stated to prescribe vaccines to all adult and older adult patients with an indication were above 75% for all recommended vaccines – Supplementary Table 5. Influenza was the vaccine prescribed by the highest proportion of physicians to all adult (93.3%) and older adult (91.6%) patients with an indication. Zoster vaccine had the lowest proportions of physicians prescribing to all patients with an indication (76% and 76.9% for adults and older adults, respectively).

Barriers to vaccine prescription

Reasons for non-prescription

The most frequently selected reason for non-prescription was the fact that the vaccine did not belong to the scope of the physicians' medical specialty. Doubts

regarding the vaccine's indication and fear of side effects were the second most frequently selected reasons for non-prescription for nine and eight of the 17 adult recommended vaccines, respectively. For each vaccine, the reasons leading to non-prescription in adults and older adults are provided in Supplementary Tables 6 and 7, respectively.

Reasons for underprescription

The proportions of prescribing physicians who stated to underprescribe vaccines were below 20% for all adult and older adult recommended vaccines – Table 2.

The high vaccine cost and lack of time during the appointment were the barriers most frequently selected by physicians for adult recommended vaccines (6 and 5 vaccines, respectively). For older adult recommended vaccines, the most commonly selected barriers were the high vaccine cost and lack of patient interest (4 vaccines each).

For each vaccine, the reasons leading to underprescription in adults and older adults are presented in Supplementary Tables 8 and 9, respectively.

Physicians' knowledge on recommended vaccines

Figure 2 shows the result on physicians' knowledge regarding all recommended vaccines per target populations. Td and Meningococcal B were the vaccines for which physicians presented the highest and lowest knowledge, respectively (mean score of 0.76 and 0.09, respectively).

Figure 2 – Knowledge on SBIIm recommended vaccines' target populations (A), dosage schedule (B) and availability in the SUS (C).

Regarding dosage schedule, Zoster was associated with the highest knowledge (80.2% of correct answers). Conversely, the lowest percentage of correct answers on this question was observed for PCV13 (1.9%).

Concerning availability in Brazil's SUS, Td and adult tetanus-diphtheria-acellular (Tdap) or Tdap-inactivated polio vaccine (IPV) were the vaccines for which physicians obtained the highest and lowest percentages of correct answers, respectively (82.3% and 20.1% of correct answers, respectively).

Knowledge by medical specialty

Results on vaccine knowledge regarding target populations, dosage schedule, and availability in the SUS by medical specialty are presented in Supplementary Tables 10, 11 and 12, respectively. The infectious disease specialists showed higher mean scores of knowledge on target populations for most vaccines, except for Hepatitis A, Tdap or Tdap-IPV, PVC13 (higher mean scores in pulmonologists) and Td (higher mean score in endocrinologists). When compared with other specialties, the proportion of correct answers regarding dosage schedule and availability in the SUS were descriptively higher among infectious disease specialists for ten and seven, respectively, of the 17 SBIIm recommended vaccines.

DISCUSSION

The burden of VPDs is increasing among older individuals with the population aging^{25, 26}. Vaccination is a key and effective public health strategy to reduce adult morbidity and mortality^{7, 25, 27}. However, studies conducted in Brazil show low VCR for some VPDs (e.g., pneumococcal disease)¹⁵, particularly among patients with comorbidities¹⁴. As physicians play a critical role in promoting vaccine uptake^{18, 19}, characterizing their behavior towards adult and older adult vaccination is both timely and important. To the best of our knowledge, this was the first study exploring the physicians' prescription habits and knowledge regarding adult and older adult vaccination in Brazil.

The proportions of prescribing physicians varied greatly across SBIm recommended vaccines. The low proportions of physicians prescribing the meningococcal and dengue vaccines are in line with the SBIm recommendations and may be explained, at least in part, by the fact that they are not routinely recommended for all adults. Indeed, the SBIm states that the indication for the meningococcal vaccines is dependent on the epidemiological scenario, while the dengue vaccine is recommended only for dengue seropositive individuals^{4, 5}. The high proportion of prescribing physicians for Yellow Fever vaccine is likely a result of the survey conducted during the Yellow Fever epidemic in Brazil (2016-2019)²⁸. It's also worth noting that the five vaccines recommended by NIP (Influenza, Hepatitis B, Yellow Fever, MMR, and Td) were also prescribed by the highest proportions of physicians. This may suggest that the official recommendations have a greater influence on vaccine prescription than those issued by SBIm.

Though the risk groups for Influenza and pneumococcal disease are similar, the results show that a markedly higher proportion of physicians prescribe the former, both to adults and older adults. A nationwide cohort study of the non-institutionalized Brazilian population estimated that appreciable proportions of adults aged ≥ 50 years present risk factors for Influenza and pneumococcal disease. Indeed, approximately 16% of adults in this age group are diabetic, 12% have heart problems, 5% have cancer and 4.5% suffer from chronic kidney disease²⁹. Thus, reducing the discrepancy between the proportions of physicians prescribing the Influenza and pneumococcal vaccines, by considerably increasing the latter, could prove beneficial to the life of millions of Brazilians. The importance of increasing the coverage of pneumococcal vaccines in the adult population has been highlighted in a study conducted at a tertiary care in Porto Alegre in patients aged 33-72 years. This study showed that approximately half (50.8%) of invasive pneumococcal disease cases that required hospital admission could have potentially been prevented through vaccination with PCV13 plus PPV23¹⁵.

The study results suggest that prescribing physicians are aware of the importance of adult and older adult vaccination. This is reflected by the fact that more than 3/4 of prescribing physicians stated to prescribe all recommended vaccines to every patient with an indication. Still, our findings also show that knowledge on vaccines' indication is not well disseminated among interviewed physicians and that different physicians may have a distinct understanding of the same vaccine's indication – Supplementary Table 10. Consequentially, physicians who did not accurately know a given vaccine's indication may have incorrectly stated to prescribe it to all patients with an indication. Moreover, doubts regarding vaccines' indication were an important factor leading to non-prescription. As such, though physicians seem mindful of the value of adult and

older adult vaccination, lack of knowledge on vaccines' indication may lead to missed opportunities to vaccinate potential vaccine recipients and increase vaccination coverage. Initiatives aimed at boosting physicians' knowledge on recommended vaccines' indications could thus prove valuable to increase the prescription of adult and older adult recommended vaccines in Brazil.

Though the present study focused on physicians' habits and perceived barriers to vaccination, it's interesting to note that lack of patient interest was among the main physician-reported barriers leading to underprescription in adults and older adults. This is in line with previous studies that explored the reasons for lack of vaccine uptake among these populations in Brazil^{30, 31}. Moreover, this finding indicates that vaccine hesitancy – the delay in vaccination schedule or refusal to receive recommended vaccines, despite their availability in health services – should be a cause for concern in Brazil³¹.

Knowledge on target populations, dosage schedule and availability in the SUS was generally low. As nearly all correct answers were defined based on the SBIm immunization schedules, one possible explanation for these results is that physicians do not routinely follow the SBIm recommendations.

The results also suggest that there may be a difficulty in incorporating newer vaccines (i.e., more recently approved) into routine clinical practice. Indeed, the study data show that physicians are more familiarized with older vaccines, such as Influenza (approved in 1997)³², Hepatitis B (approved in 1993)³³, and Td (used since 1975)³⁴. This is reflected by the fact that these were among the four vaccines prescribed by the highest proportions of physicians to both adults and older adults and for which physicians presented the highest knowledge. Conversely, the most

recently approved vaccines in Brazil (Dengue and Meningococcal B, approved in 2015^{35, 36}, and Meningococcal Conjugate ACWY, approved in 2014³⁷) were prescribed by the lowest proportions of physicians and were generally among those associated with the lowest knowledge, particularly for target populations and dosage schedule. In addition to not being routinely recommended for all adults, inadequate knowledge on these vaccines may have also contributed to the low proportions of prescribing physicians observed. This is supported by the fact that doubts regarding indication was the second most commonly selected reason leading to non-prescription of more recently approved vaccines (Supplementary Table 6). Thus, these results highlight the need for initiatives aimed at promoting physicians' knowledge on SBIm recommended vaccines to focus on the most recently approved ones.

A recent study evaluated the overall coverage of NIP provided vaccines between 1994 and 2019 and explored differences in coverage between Brazilian regions³⁸. The Midwest region showed the highest coverage rate (77.1%), approximately 3.6% above the national average of 73.5%. All remaining regions showed similar coverages, ranging from 72.9% (Southeast) to 73.6% (North). Though evaluating different vaccination practices across Brazilian regions was not an objective of this study, it's worth noting that more than half (54%) of participating physicians were from the Southeast region (reflecting health care professionals geographic concentration, in line with the planned stratification), while only 8% were from the Midwest.

This study has several limitations. On one hand, the generalizability of our findings is limited by three main factors. First, only seven medical specialties were included in the study. Second, although responding physicians were stratified by medical

specialty and Brazilian region (Supplementary Table 13), the stratification of the study sample did not encompass other relevant characteristics, which may have differed between responding physicians and the general population of physicians in Brazil. For instance, the study population was comprised of a considerably lower proportion of physicians working exclusively in the public sector (4.8% vs. 21.6% in the Brazilian population of physicians)²⁴. Third, the study sample may have been comprised of physicians particularly interested in the topic of adult and older adult vaccination, as suggested by the high number of invitations (76 104) required to obtain 1068 surveys and by the fact that most physicians (89.8%) stated to routinely recommend vaccines.

On the other hand, limitations related to the survey design and the methodology followed to define correct answers may have impacted the results obtained and should be considered during their interpretation. First, underprescription was defined as prescribing less than recommended according to the SBIm and NIP. However, the SBIm and NIP differ in the number of vaccines recommended to adults (5 versus 17, respectively) and older adults (4 versus 12, respectively). Thus, a physician may be compliant with the NIP recommendations while simultaneously prescribing less than recommended by the SBIm. As a result, underprescription may have been underestimated – for instance, physicians prescribing a given vaccine less than recommended by the SBIm may have stated not to underprescribe it if they considered the NIP recommendations only. Additionally, no immunization recommendations from SBIm and the NIP were provided in the survey. As physicians were expected to use their own knowledge on these recommendations to identify and report underprescription, those not aware of their full extent may have failed to do so. Second, physicians' knowledge on target populations may have been

overestimated for vaccines recommended for both adults and older adults (except for PCV13 and PPV23). This is because physicians who selected “All patients (regardless of age and risk group)” as the target population were given the total score of one point, even without specifying any special population according to the SBIm immunization schedule²⁰ – Supplementary Table 1. Third, the correct answers regarding availability in the SUS focused on whether the vaccines were available free of charge at the BHU according to the SBIm immunization schedules^{4, 5}. Nonetheless, certain vaccines are available free of charge at the Special Immunobiological Reference Centers (CRIES), which are a part of the SUS. Physicians may have thus considered the availability of vaccines in the CRIES when responding to this question, which may have impacted the results.

In conclusion, a considerable variability of prescribing habits was observed in this study across SBIm recommended vaccines. Although most prescribing physicians seem to be aware of the importance of adult and older adult vaccination, knowledge deficits on vaccines’ target populations, dosage schedule, and availability in the SUS may hamper their ability to prescribe vaccines to all patients with an indication. Initiatives to increase the physicians’ knowledge (particularly on recently approved vaccines) are recommended to increase the VCR among the adult and older adult Brazilian populations, as is the adoption of measures to tackle the most common barriers to vaccination (high cost, lack of time during appointments, and lack of patient interest).

Acknowledgements

"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, provided financial support for the study." The authors would like to thank Dr. Edson Moreira for his review and data analysis and Leila Carvalho (employee of MSD Brazil at the time of the study) for her scientific contributions. We acknowledge CTI Clinical Trial & Consulting Services for all editorial support.

Author Contributions

All authors have read and agreed to the published version of the manuscript and attest that they meet the International Committee of Medical Journal Editors criteria for authorship.

Conflicts of interest

Fernando B Serra, Paula M Batista and Thais N F Moreira are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, who may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA. Diogo Ribeiro is an employee of CTI Clinical Trial & Consulting Services. This company received honoraria from the project funder for support in the study planning and manuscript development.

REFERENCES

- [1] Williams WW. Surveillance of Vaccination Coverage Among Adult Populations — United States, 2014. *MMWR Surveill Summ* 2016;65. <https://doi.org/10.15585/mmwr.ss6501a1>.
- [2] Césare N, Mota TF, Lopes FFL, Lima ACM, Luzardo R, Quintanilha LF, et al. Longitudinal profiling of the vaccination coverage in Brazil reveals a recent change in the patterns hallmarked by differential reduction across regions. *Int J Infect Dis* 2020;98:275–80. <https://doi.org/10.1016/j.ijid.2020.06.092>.
- [3] Programa Nacional de Imunizações. Anexo III - Calendário do Adulto e do Idoso [cited 2021 jun 07]. Available at: <https://central3.to.gov.br/arquivo/517645/>.
- [4] Sociedade Brasileira de Imunizações (SBIm). Calendário de Vacinação SBIm ADULTO, Recomendações da Sociedade Brasileira de Imunizações (SBIm) - 2017/2018. 2017 [cited 2017 sep 06]. Available at: <https://sbim.org.br/images/calendarios/calend-sbim-adulto.pdf>.
- [5] Sociedade Brasileira de Imunizações (SBIm). Calendário de Vacinação SBIm IDOSO, Recomendações da Sociedade Brasileira de Imunizações (SBIm) - 2017/2018. 2017 [cited 2017 sep 06]. Available at: <https://sbim.org.br/images/calendarios/calend-sbim-idoso.pdf>.
- [6] Sociedade Brasileira de Imunizações (SBIm). Calendários de Vacinação - Pacientes Especiais 2019-2020. 2019 [cited 2020 jan 08]. Available at: <https://sbim.org.br/publicacoes/guias/1138-calendarios-de-vacinacao-sbim-pacientes-especiais-2019-2020>.
- [7] Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, et al. Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAIID). *Hum Vaccines Immunother* 2016;12:1777–94. <https://doi.org/10.1080/21645515.2016.1150396>.
- [8] Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet Lond Engl* 2012;380:37–43. [https://doi.org/10.1016/S0140-6736\(12\)60240-2](https://doi.org/10.1016/S0140-6736(12)60240-2).
- [9] Maggi S. Vaccination and healthy aging. *Expert Rev Vaccines* 2010;9:3–6. <https://doi.org/10.1586/erv.10.26>.
- [10] High K, Bradley S, Loeb M, Palmer R, Quagliarello V, Yoshikawa T. A New Paradigm for Clinical Investigation of Infectious Syndromes in Older Adults: Assessing Functional Status as a Risk Factor and Outcome Measure. *J Am Geriatr Soc* 2005;53:528–35. <https://doi.org/10.1111/j.1532-5415.2005.53240.x>.
- [11] Doherty TM, Connolly MP, Del Giudice G, Flamaing J, Goronzy JJ, Grubeck-Loebenstein B, et al. Vaccination programs for older adults in an era of demographic change. *Eur Geriatr Med* 2018;9:289–300. <https://doi.org/10.1007/s41999-018-0040-8>.
- [12] Giese C, Mereckiene J, Danis K, O'Donnell J, O'Flanagan D, Cotter S. Low vaccination coverage for seasonal influenza and pneumococcal disease among adults at-risk and health care workers in Ireland, 2013: The key role of GPs in recommending vaccination. *Vaccine* 2016;34:3657–62. <https://doi.org/10.1016/j.vaccine.2016.05.028>.
- [13] Williams WW, Lu P-J, O'Halloran A, Bridges CB, Kim DK, Pilishvili T, et al. Vaccination Coverage Among Adults, Excluding Influenza Vaccination — United States, 2013. *MMWR Morb Mortal Wkly Rep* 2015;64:95–102.
- [14] Monteiro CN, Gianini RJ, Stopa SR, Segri NJ, Barros MB de A, Cesar CLG, et al. Vaccination coverage and use of the Brazilian Health System for vaccination against influenza and pneumonia in adults and elderly with self-reported diabetes, municipality of São Paulo, 2003, 2008 and 2015. *Epidemiol E Serv Saude Rev Sist Unico Saude Bras* 2018;27:e2017272. <https://doi.org/10.5123/s1679-49742018000200006>.

- [15] Dullius CR, Zani L, Chatkin JM. Theoretical pneumococcal vaccine coverage: analysis of serotypes isolated from inpatients at a tertiary care hospital. *J Bras Pneumol Publicacao Of Soc Bras Pneumol E Tisiologia* 2018;44:361–6. <https://doi.org/10.1590/S1806-37562017000000056>.
- [16] Sato APS. What is the importance of vaccine hesitancy in the drop of vaccination coverage in Brazil? *Rev Saúde Pública* 2018;52. <https://doi.org/10.11606/S1518-8787.2018052001199>.
- [17] Azambuja HCS, Carrijo MF, Martins TCR, Luchesi BM. O impacto da vacinação contra influenza na morbimortalidade dos idosos nas regiões do Brasil entre 2010 e 2019. *Cad Saúde Pública* 2020;36. <https://doi.org/10.1590/0102-311X00040120>.
- [18] Sevin AM, Romeo C, Gagne B, Brown NV, Rodis JL. Factors influencing adults' immunization practices: a pilot survey study of a diverse, urban community in central Ohio. *BMC Public Health*. 2016;16:424.
- [19] Winston CA, Wortley PM, Lees KA. Factors associated with vaccination of medicare beneficiaries in five U.S. communities: Results from the racial and ethnic adult disparities in immunization initiative survey, 2003. *J Am Geriatr Soc*. 2006 Feb;54(2):303–10.
- [20] Sociedade Brasileira de Imunizações (SBIm). Calendários de Vacinação - Pacientes Especiais 2015-2016. 2016 [cited 2017 sep 06]. Available at: <https://www.previnavacinas.com.br/calendarios/calend-sbim-pacientes-especiais.pdf>.
- [21] Ministério da Saúde. Nota Informativa Nº 135-SEI/2017-CGPNI/DEVIT/SVS/MS. [Internet] 2017 Accessed on 13 Nov 2018]. Available at: <http://www.smp.org.br/arquivos/site/protocolo-meningite-5-edicao-completo-3-2.pdf>.
- [22] Ministério da Saúde. Calendário Nacional de Vacinação 2018 . [Internet] 2018 [Accessed on 12 Jul 2019]. Available at: <http://portal.arquivos.saude.gov.br/campanhas/pni/>.
- [23] Conselho Federal de Medicina. Médicos ativos por região. [Internet] 2017 [Accessed on 16 Aug 2017]. Available at: http://portal.cfm.org.br/index.php?option=com_estatistica.
- [24] Mário Scheffer et al. Demografia Médica no Brasil 2015. [Internet] 2015 [Accessed on 06 Set 2017]. Available at: <https://www.usp.br/agen/wpcontent/uploads/DemografiaMedica30nov2015.pdf>.
- [25] Sauer M, Vasudevan P, Meghani A, Luthra K, Garcia C, Knoll MD, et al. Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries. *Vaccine* 2021;39:1556–64. <https://doi.org/10.1016/j.vaccine.2021.01.066>.
- [26] Doherty TM, Giudice GD, Maggi S. Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion. *Ann Med* 2019;51:128–40. <https://doi.org/10.1080/07853890.2019.1588470>.
- [27] Mehta B, Chawla S, Kumar Dharma V, Jindal H, Bhatt B. Adult immunization. *Hum Vaccines Immunother* 2014;10:306–9. <https://doi.org/10.4161/hv.26797>.
- [28] de Oliveira Figueiredo P, Stoffella-Dutra AG, Barbosa Costa G, Silva de Oliveira J, Dourado Amaral C, Duarte Santos J, et al. Re-Emergence of Yellow Fever in Brazil during 2016–2019: Challenges, Lessons Learned, and Perspectives. *Viruses* 2020;12. <https://doi.org/10.3390/v12111233>.
- [29] Nunes BP, Batista SRR, Andrade FB de, Souza Junior PRB de, Lima-Costa MF, Facchini LA. Multimorbidity: The Brazilian Longitudinal Study of Aging (ELSI-Brazil). *Rev Saude Publica* 2018;52Suppl 2:10s. <https://doi.org/10.11606/S1518-8787.2018052000637>.
- [30] Francisco PMSB, Barros MB de A, Cordeiro MRD. Vacinação contra influenza em idosos: prevalência, fatores associados e motivos da não-adesão em Campinas, São Paulo, Brasil. *Cad Saúde Pública* 2011;27:417–26. <https://doi.org/10.1590/S0102-311X2011000300003>.

- [31] Dip RM, Cabrera MAS. Influenza vaccination in non-institutionalized elderly: a population-based study in a medium-sized city in Southern Brazil. *Cad Saúde Pública* 2010;26:1035–44. <https://doi.org/10.1590/S0102-311X2010000500025>.
- [32] Agência Nacional de Vigilância Sanitária. Vacina Influenza trivalente (fragmentada, inativada). [cited 2019 sep 04]. Available at: <https://consultas.anvisa.gov.br/#/medicamentos/250000082889634/?substancia=19850&situacaoRegistro=C>.
- [33] Agência Nacional de Vigilância Sanitária. Engerix B. [cited 2019 sep 04]. Available at: <https://consultas.anvisa.gov.br/#/medicamentos/2500100359787/?substancia=19447>.
- [34] Coordenadoria de Controle de Doenças, Centro de Vigilância Epidemiológica. Calendário de Vacinação no Estado de São Paulo. [cited 2021 jun 18]. Available at: https://www.saude.sp.gov.br/resources/cve-centro-de-vigilancia-epidemiologica/areas-de-vigilancia/imunizacao/doc/imuni_shcalen.pdf.
- [35] Agência Nacional de Vigilância Sanitária. Dengvaxia. [cited 2019 sep 04]. Available at: <https://consultas.anvisa.gov.br/#/medicamentos/25351193951201526/?substancia=25982&situacaoRegistro=V>.
- [36] Agência Nacional de Vigilância Sanitária. Vacina adsorvida meningocócica B (recombinante). [cited 2019 sep 04]. Available at: <http://www.vacinar.com.br/bulas/BulaBexsero.pdf>.
- [37] Agência Nacional de Vigilância Sanitária. Menveo. [cited 2019 sep 04]. Available at: <https://consultas.anvisa.gov.br/#/medicamentos/25351945177201612/?substancia=26000&situacaoRegistro=V>.
- [38] Nóvoa T d'Avila, Cordovil VR, Pantoja GM, Ribeiro MES, Cunha AC dos S, Benjamin AIM, et al. Cobertura vacinal do programa nacional de imunizações (PNI)/Vacinal coverage of the national immunization program (PNI). *Braz J Health Rev* 2020;3:7863–73. <https://doi.org/10.34119/bjhrv3n4-053>.

TABLES

Table 1 – Participants sociodemographic and clinical practice characteristics

	Total (n=1068)
Age (years)	44.70 ± 9.91
Sex (female)	574 (53.7)
Brazilian region	
North	48 (4.5)
Northeast	191 (17.9)
Midwest	88 (8.2)
Southeast	580 (54.3)
South	161 (15.1)
Medical specialty best defining clinical practice	
Cardiology	244 (22.8)
General Practice/Family Practice	85 (8.0)
Endocrinology	80 (7.5)
Geriatrics	26 (2.4)
Gynecology	515 (48.2)
Infectious Disease	59 (5.5)
Pulmonology	59 (5.5)
Place(s) of work	
Public hospital	569 (53.3)
Private hospital	604 (56.5)
Public medical office	367 (34.4)
Private medical office for patients with health insurance plans	838 (78.5)
Private medical office (payment is made exclusively by the patient)	620 (58.0)
Years of medical specialty practice ^a (years) (n=1063)	17.06 ± 9.96
Number of patients cared for during a regular work week	113.09 ± 76.72
Routinely recommends vaccines to patients	959 (89.8)
Vaccine prescription as part of medical practice (n=959)	944 (98.4)
Characterization of vaccine prescription in clinical practice (n=944)	
Very common	383 (40.6)
Common	457 (48.4)
Not very common	104 (11.0)
Time prescribing vaccines to adult and older adult patients (years) (n=955)	13.85 ± 8.28
Vaccines prescribed per week to adult and older adult patients	
None	62 (5.8)
1-5	388 (36.3)
6-10	279 (26.1)
11-20	220 (20.6)

21-50	92 (8.6)
>50	27 (2.5)

577 Results are displayed as n (%) or mean $\pm$ standard deviation.
578 N=1068 unless otherwise specified.
579 All summary statistics include only non-missing values.
580 ^aExcluding years of medical residency/specialization.

581 **Table 2** – Physicians prescribing and underprescribing vaccines recommended by the **Brazilian Society of Immunization** to adult and older
582 adults

Vaccines	Physicians who stated to prescribe the vaccine ^a % (95% CI)		Prescribing physicians who stated to underprescribe the vaccine ^b % (physicians who stated to underprescribe the vaccine out of prescribing physicians)	
	Adults	Older adults	Adults	Older adults
Bivalent HPV	46.7 (43.7-49.7)	NA	10.6 (53/449)	NA
Dengue	19.9 (17.5-22.3)	NA	13.6 (29/213)	NA
Hepatitis A	34.9 (32.1-37.8)	24.1 (21.5-26.6)	18.0 (67/373)	12.5 (32/257)
Hepatitis B	86.6 (84.6-88.7)	59.0 (56.0-61.9)	9.3 (86/925)	10.6 (67/630)
Hepatitis A and B	46.7 (43.7-49.7)	26.1 (23.5-28.8)	17.4 (87/499)	9.0 (37/257)
Herpes zoster	46.4 (43.5-49.4)	48.7 (45.7-51.7)	19.6 (97/496)	19.6 (102/520)
Influenza	94.9 (93.5-96.2)	92.8 (91.2-94.3)	5.3 (39/216)	7.5 (17/160)
Meningococcal B	18.8 (16.5-21.2)	NA	14.4 (29/201)	NA
Meningococcal Conjugate ACWY	20.2 (17.8-22.6)	15.0 (12.8-17.1)	18.1 (82/373)	10.6 (67/77)
MMR	51.5 (48.5-54.5)	23.3 (20.8-25.9)	14.7 (81/550)	8.8 (22/249)
PCV13	49.4 (46.4-52.4)	50.2 (47.2-53.2)	14.6 (77/528)	14.7 (79/536)
PPV23	46.3 (43.3-49.2)	50.9 (47.9-53.9)	10.7 (53/494)	12.9 (70/544)
Quadrivalent HPV	59.7 (56.8-62.7)	NA	7.2 (46/638)	NA
Td	72.5 (69.8-75.2)	52.1 (49.1-55.1)	11.5 (89/774)	12.9 (72/556)
Tdap or Tdap-IPV	67.3 (64.5-70.1)	35.4 (32.5-38.3)	9.9 (71/719)	14.8 (56/378)
Varicella	26.1 (23.5-28.8)	NA	12.5 (35/279)	NA
Yellow Fever	77.7 (75.2-80.2)	58.5 (55.6-61.5)	10.2 (85/830)	11.5 (72/625)

583 MMR, measles, mumps and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, inactivated polio vaccine; Td: Tetanus and diphtheria; PCV13, 13-valent pneumococcal
584 conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus, NA, not applicable.

585 ^aPrescribing physicians include those prescribing vaccines to all or part of their patients with an indication.

586 ^bFor each vaccine, the proportion of underprescription was determined based on the number of physicians who stated to prescribe it.

587

588 **BOX**

589 **Box 1** – Brazilian Society of Immunization's recommendations for adults and older adults at the time of the study (2017-2018)^{4, 5, 20}

Vaccine	Indicated for adults (20-59 years)	Indicated for older adults (≥60 years)	Special populations	Standard vaccination schedule/Dosage Schedule ^a
Dengue	Yes, for Dengue seropositive individuals, up to 45 years	No	- No special populations	Three doses (0, 1, 12 months)
Hepatitis: Hepatitis A / Hepatitis B / Combined Hepatitis A and B	Yes	Yes ^b	<ul style="list-style-type: none"> - Chronic liver disease - Neoplasms or use of immunosuppressive drugs - Chronic kidney disease - Anatomical and functional asplenia - Rheumatic disease - Primary immunodeficiencies - HIV/AIDS - Solid organ transplant candidates and recipients - Hematopoietic stem cell transplant recipients - Diabetes mellitus (Hepatitis B only) - Coagulopathies (Hepatitis A and Hepatitis B) - Deposit diseases (Hepatitis A and Hepatitis B) - Alcoholism (Hepatitis A and Hepatitis B) - Cystic fibrosis (Hepatitis A and Hepatitis B) - Trisomies (Hepatitis A and Hepatitis B) 	Hepatitis A: Three doses (0, 1-2, 6 months)
				Hepatitis B / Hepatitis A and B: Two doses (0, 6 months)
Herpes zoster	Yes, for individuals ≥50 years old (at physicians' discretion)	Yes	<ul style="list-style-type: none"> - Chronic liver disease^c - Chronic cardiac disease and/or chronic lung disease^c - Chronic kidney disease^c - Anatomical and functional asplenia - Rheumatic disease^c - Primary immunodeficiencies^c 	One dose
HPV (Bivalent or Quadrivalent)	Yes ^d	No	<ul style="list-style-type: none"> - Rheumatic disease - Primary immunodeficiencies - HIV/AIDS 	3 doses
Influenza	Yes	Yes	<ul style="list-style-type: none"> - Chronic liver disease - Chronic cardiac disease and/or chronic lung disease - Neoplasms or use of immunosuppressive drugs 	One annual dose

			<ul style="list-style-type: none"> - Chronic kidney disease - Anatomical and functional asplenia - Rheumatic disease - Primary immunodeficiencies - HIV/AIDS - Solid organ transplant candidates and recipients - Hematopoietic stem cell transplant recipients - Diabetes mellitus - Chronic use of acetylsalicylic acid - Deposit diseases - Alcoholism - Smoking - Cystic fibrosis - Trisomies - Crippling neurological disease - Liquoric fistula 	
Meningococcal B	Yes ^e	No	<ul style="list-style-type: none"> - Chronic liver disease - Neoplasms or use of immunosuppressive drugs - Chronic kidney disease - Anatomical and functional asplenia - Rheumatic disease - Primary immunodeficiencies - HIV/AIDS - Solid organ transplant candidates and recipients - Hematopoietic stem cell transplant recipients - Deposit diseases - Trisomies - Crippling neurological disease - Liquoric fistula 	Two doses (1-2 month interval between immunizations)
Meningococcal Conjugate ACWY	Yes ^e	Yes ^e	<ul style="list-style-type: none"> - Chronic liver disease - Neoplasms or use of immunosuppressive drugs - Chronic kidney disease - Anatomical and functional asplenia - Rheumatic disease - Primary immunodeficiencies - HIV/AIDS - Solid organ transplant candidates and recipients - Hematopoietic stem cell transplant recipients - Deposit diseases - Trisomies - Crippling neurological disease 	One dose

			- Liquoric fistula	
MMR	Yes. The use in immunocompromised patients should be evaluated by the physician	Yes. Vaccination is not routine but may be recommended at the physicians' discretion (e.g., in case of outbreaks, travel)	<ul style="list-style-type: none"> - HIV/AIDS^f - Solid organ transplant candidates and recipients^g - Hematopoietic stem cell transplant recipients 	Two doses in individuals over 1 year of age (1 month interval between immunizations)
PCV13 and PPV23	Yes, in individuals aged 50-59 years (at physicians' discretion)	Yes	<ul style="list-style-type: none"> - Chronic liver disease - Chronic cardiac disease and/or chronic lung disease - Neoplasms or use of immunosuppressive drugs - Chronic kidney disease - Anatomical and functional asplenia - Rheumatic disease - Primary immunodeficiencies - HIV/AIDS - Solid organ transplant candidates and recipients - Hematopoietic stem cell transplant recipients - Diabetes mellitus - Deposit diseases - Alcoholism - Smoking - Cystic fibrosis - Trisomies - Crippling neurological disease - Liquoric fistula 	One dose of PCV13 followed by a dose of PPV23 6-12 months later, and a second dose of PPV23 five years after the first
Tdap or Tdap-IPV Td	Yes	Yes	<p>Tdap or Tdap-IPV:</p> <ul style="list-style-type: none"> - Chronic cardiac disease and/or chronic lung disease - Neoplasms or use of immunosuppressive drugs - HIV/AIDS - Solid organ transplant candidates and recipients - Hematopoietic stem cell transplant recipients - Deposit diseases - Trisomies - Crippling neurological disease <p>Td: No special populations</p>	<ul style="list-style-type: none"> - <u>With complete basic vaccination schedule:</u> Tdap booster every ten years - <u>With incomplete basic vaccination schedule:</u> one dose of Tdap at any time and complete the basic vaccination with Td - <u>Unvaccinated and/or unknown vaccination history:</u> one dose of Tdap and 2 doses of Td (0, 2, 4 to 8 months) - <u>Individuals who intend to travel to countries where polio is endemic:</u> Tdap combined with Tdap-IPV

Varicella	Yes, for susceptible individuals	No	<ul style="list-style-type: none"> - Chronic liver disease^h - Chronic cardiac disease and/or chronic lung disease^h - Chronic kidney disease^h - Anatomical and functional asplenia^h - Rheumatic disease^h - Primary immunodeficiencies^{h,i} - HIV/AIDS^f - Solid organ transplant candidates and recipients^{g,h} - Hematopoietic stem cell transplant recipients^h - Diabetes mellitus - Chronic use of acetylsalicylic acid - Deposit diseases - Chronic dermatologic diseases - Alcoholism - Cystic fibrosis - Trisomies - Crippling neurological disease 	Two doses (1-2 month interval between immunizations)
Yellow Fever	Yes ^j	Yes ^j	<ul style="list-style-type: none"> - HIV/AIDS^f - Solid organ transplant candidates and recipients^g - Hematopoietic stem cell transplant recipients^k 	One dose

HPV, human papillomavirus; HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency syndrome; MMR, measles, mumps and rubella; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; Tdap, adult tetanus-diphtheria-acellular; IPV, inactivated polio vaccine; Td: Tetanus and diphtheria

^aFor special populations, some vaccines have a schedule that differs from the standard vaccination schedule.

^bImmunization with Hepatitis A vaccine is recommended in situations of exposure or disease outbreak; It is uncommon to find susceptible individuals over 60 years old – serology can be requested to define whether or not to vaccinate

^cIn the absence of immunosuppression

^dBivalent HPV: licensed for girls and women from 9 years of age; Quadrivalent HPV: licensed for girls and women from 9 to 45 years and boys and men from 9 to 26 years

^eIndication is dependent on the epidemiological scenario

^fContraindicated in patients with CD4 <200 cells/mm³ (<15%)

^gContraindicated in the post-transplant setting (vaccines may be administered only when the patient is immunocompetent)

^hContraindicated in patients with severe immunosuppression

ⁱContraindicated in patients with cellular or cellular and humoral immunity deficiency

^jFor individuals not previously vaccinated, one dose for residents or travelers to areas with a vaccination recommendation. It can also be recommended to meet the health requirements of certain international trips. In both cases, vaccine should be administered at least 10 days before the trip

^kThe indication is dependent on epidemiological risk and the patient's immunological status

590

591

594 **Figure 1** – Information collected on prescription habits for adult and older adult recommended vaccines. SBIm, Brazilian Society of Immunization;
595 NIP, National Immunization Program

596

597 **Figure 2** – Knowledge on SBI recommended vaccines' target populations (A), dosage schedule (B) and availability in the SUS (C). Td,
 598 Tetanus and diphtheria; Tdap, adult tetanus-diphtheria-accelullar; IPV, inactivated polio vaccine; MMR, Measles, Mumps, and Rubella; PPV23,
 599 23-valent pneumococcal polysaccharide vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; HPV, human papillomavirus